ECOG-ACRIN logo[19516]275×75ECOG-ACRIN logo[19516]275×75ECOG-ACRIN logo[19516]275×75ECOG-ACRIN logo[19516]275×75
  • Home
  • Archive
  • Contact
✕

demo

  • Home
  • demo
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Adolescent and young adult oncology
  • Advanced practice providers
  • Advocacy
  • Artificial intelligence (AI)
  • Bladder cancer
  • Brain tumors
  • Breast cancer
  • Cancer care delivery research
  • Cancer control and survivorship
  • ComboMATCH precision medicine trial
  • Comis Symposium
  • Community oncology
  • Data science
  • Federally-funded cancer research
  • Gastrointestinal cancers
  • Genitourinary cancers
  • Geriatric oncology
  • Group meeting
  • Head and neck cancer
  • Health equity
  • Imaging
  • In memory
  • Kidney cancer
  • Leadership
  • Leukemia
  • Lung cancer
  • Lymphoma
  • Melanoma
  • Membership
  • Mentorship
  • Merkel cell carcinoma
  • Mesothelioma
  • Myelodysplastic syndromes
  • Myeloma
  • myeloMATCH
  • NCI-MATCH precision medicine trial
  • Pancreatic cancer
  • Patient-reported outcomes
  • Pragmatic clinical trials
  • Precision medicine
  • PrECOG
  • Prevention screening and surveillance
  • Prostate cancer
  • Public-private partnerships
  • Real-world data
  • Research policy
  • Sarcoma
  • Social determinants of health
  • Symptom science and treatment toxicity
  • TMIST mammography trial
  • Tobacco cessation
September 14, 2020
PrECOG logo
September 14, 2020
Categories
  • Trial Results

Trial Results: PALbociclib CoLlaborative Adjuvant Study (PALLAS)

A second interim analysis of this international adjuvant study for HR+, HER2- early breast cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
Do you like it?
0 Read more

A blog to share information with our members, staff, and the cancer research community

✕

Categories

  • From the Co-Chairs
  • Active Clinical Trials
  • Institution Spotlights
  • Special Topics
  • People
  • News in Brief
  • Trial Results
  • Active ECOG-ACRIN Trials
  • ECOG-ACRIN.org
STAY UP TO DATE

Opt in to ensure we deliver this monthly blog directly to your inbox. We will never share your email.

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc